Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

22 september 2014 bijgewerkt door: AbbVie (prior sponsor, Abbott)

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

This is an open-label study designed to establish the safety and effectiveness of adalimumab in the treatment of moderate to severe plaque psoriasis after 24 weeks of treatment.

Studie Overzicht

Toestand

Voltooid

Interventie / Behandeling

Gedetailleerde beschrijving

During the treatment period, participants will receive an initial adalimumab 80 milligram (mg) subcutaneous (sc) dose, followed by adalimumab 40 mg sc every other week starting one week after initial dose. Safety and effectiveness assessments will be completed at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 24. Participants may discontinue adalimumab treatment at any time during study participation. Participants that end study participation early will have a Premature Discontinuation visit. All participants who do not initiate commercial Humira® will have a follow-up phone call 70 days after the last administration of study drug to obtain information on any new or ongoing Adverse Events (AEs). The 70-day follow-up phone call will not be required for any participant that initiates adalimumab therapy not supplied in the context of the clinical trial after the end of study participation.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

50

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Ekaterinburg, Russische Federatie, 620076
        • Site Reference ID/Investigator# 67547
      • Kazan, Russische Federatie, 420012
        • Site Reference ID/Investigator# 78433
      • Moscow, Russische Federatie, 107076
        • Site Reference ID/Investigator# 67542
      • Saratov, Russische Federatie, 410028
        • Site Reference ID/Investigator# 67546
      • Smolensk, Russische Federatie, 214018
        • Site Reference ID/Investigator# 78417
      • St. Petersburg, Russische Federatie, 190013
        • Site Reference ID/Investigator# 78413
      • St. Petersburg, Russische Federatie, 194044
        • Site Reference ID/Investigator# 67545

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

A patient will be eligible for study participation if he/she meets the following criteria:

  1. Male and female patients ≥ 18 years of age.
  2. Clinical diagnosis of psoriasis for at least 6 months as determined by patient interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator.
  3. Stable plaque psoriasis for at least 2 months before Screening and Baseline visits as determined by patient interview of his/her medical history.
  4. Moderate to severe plaque psoriasis defined by ≥ 10% Body Surface Area (BSA) involvement at the Baseline visit.
  5. PASI (Psoriasis Area and Severity Index) score ≥ 10 at the Baseline visit.

Exclusion Criteria:

  1. Diagnosis of erythrodermic psoriasis, pustular psoriasis, medication induced or medication-exacerbated psoriasis or new onset of guttate psoriasis.
  2. Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with evaluation of psoriasis.
  3. Patient who cannot discontinue topical therapies for the treatment of psoriasis such as corticosteroids, vitamin D analogs, or retinoids at least 14 days prior to the Baseline (Week 0) visit and during the study. Participants are allowed to use:

    • Shampoos that contain no corticosteroid;
    • Bland (without beta or alpha hydroxy acids or containing no psoriasis treatment) emollients;
    • Low potency topical corticosteroids on the palms, soles, face, inframammary area, and groin only.
  4. Patient who cannot avoid UVB (Ultraviolet-B) phototherapy for at least 14 days prior to the Baseline (Week 0) visit and during the study.
  5. Patient who cannot avoid PUVA (psoralen + ultraviolet A) phototherapy for at least 28 days prior to the Baseline (Week 0) visit and during the study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Ander: Adalimumab
Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
Andere namen:
  • ABT-D2E7
  • Humira

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24
Tijdsspanne: Baseline and Week 24
The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Week 24

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Achieving a Physician's Global Assessment of Clear
Tijdsspanne: Weeks 2, 4, 8, 12, 16 and 24

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories:

  • 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared;
  • 1: Occasional fine scale over <5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal;
  • 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild;
  • 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate;
  • 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked;
  • 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe.

The percentage of participants achieving a PGA score of clear (0) is reported.

Weeks 2, 4, 8, 12, 16 and 24
Percentage of Participants Achieving a Physician's Global Assessment of Clear or Minimal
Tijdsspanne: Weeks 2, 4, 8, 12, 16 and 24

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories:

  • 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared;
  • 1: Occasional fine scale over <5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal;
  • 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild;
  • 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate;
  • 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked;
  • 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe.

The percentage of participants achieving a PGA score of clear (0) or minimal (1) is reported.

Weeks 2, 4, 8, 12, 16 and 24
Percentage of Participants Achieving a One Grade Improvement in Physician's Global Assessment (PGA)
Tijdsspanne: Baseline and Weeks 2, 4, 8, 12, 16 and 24

The PGA is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories:

  • 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared;
  • 1: Occasional fine scale over <5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal;
  • 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild;
  • 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate;
  • 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked;
  • 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe.

The percentage of participants achieving a shift from Baseline to a less severe category is reported.

Baseline and Weeks 2, 4, 8, 12, 16 and 24
Percentage of Participants Achieving a PASI 50 Response
Tijdsspanne: Baseline and Weeks 2, 4, 8, 12, 16, and 24
The percentage of participants with a ≥ 50% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants Achieving a PASI 75 Response
Tijdsspanne: Baseline and Weeks 2, 4, 8, 12, and 16
The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Weeks 2, 4, 8, 12, and 16
Percentage of Participants Achieving a PASI 90 Response
Tijdsspanne: Baseline and Weeks 2, 4, 8, 12, 16, and 24
The percentage of participants with a ≥ 90% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants Achieving a PASI 100 Response
Tijdsspanne: Baseline and Weeks 2, 4, 8, 12, 16, and 24
The percentage of participants with a 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
Tijdsspanne: Baseline and Weeks 2, 4, 8, 12, 16, and 24

PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value * 100. A negative change from Baseline indicates improvement.

Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percent Change From Baseline in Dermatology Life Quality Index (DLQI)
Tijdsspanne: Baseline and Weeks 8, 12, and 24
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value * 100. A negative change from Baseline indicates improvement.
Baseline and Weeks 8, 12, and 24
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
Tijdsspanne: Baseline and Week 24

NAPSI grades nails for both nail matrix psoriasis and nail bed psoriasis. The most affected fingernail was determined at Baseline and used for the analysis.

Nail matrix psoriasis consists of any of the following: pitting, leukonychia, red spots in the lunula, or nail plate crumbling. Nail bed psoriasis is the presence or absence of onycholysis, splinter hemorrhages, oil drop (salman patch) discoloration or nail bed hyperkeratosis. Scoring for each is based on the following scale:

  • 0 = none;
  • 1 = present in 1/4 nail quadrants;
  • 2 = present in 2/4 nail quadrants;
  • 3 = present in 3/4 nail quadrants;
  • 4 = present in 4/4 nail quadrants.

The sum of these two scores is the total score for the nail, and ranges from 0 (no nail psoriasis) to 8 (psoriasis in 4/4 nail quadrants). Change from Baseline is presented as a percentage of the Baseline value, calculated as: Week 24 value - Baseline value / Baseline value * 100. A negative change from Baseline indicates improvement.

Baseline and Week 24

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change From Baseline in Hemoglobin
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Hematocrit
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events. The hematocrit measures the volume of red blood cells compared to the total blood volume (red blood cells and plasma).
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Red Blood Cell Count
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Blood Cell Counts
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Erythrocyte Sedimentation Rate
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Alanine Aminotransferase
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Aspartate Aminotransferase
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Alkaline Phosphatase
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Total Bilirubin
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Creatinine
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Blood Urea Nitrogen (BUN)
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Uric Acid
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Inorganic Phosphate
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Calcium, Sodium and Potassium
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Glucose
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Albumin
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Total Protein
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Cholesterol
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Triglycerides
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP)
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Urine pH
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Urine Specific Gravity
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Blood Pressure
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Pulse
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Respiratory Rate
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Weight
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Body Temperature
Tijdsspanne: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Number of Participants With Adverse Events (AEs)
Tijdsspanne: From the first dose of study drug until 70 days after the last dose (up to 33 weeks).

An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment.

The investigator rated the severity of each AE as either:

Mild: The AE is transient and easily tolerated; Moderate: The AE causes the participant discomfort and interrupts usual activities.

Severe: The AE causes considerable interference with usual activities and may be incapacitating or life-threatening.

A serious adverse event (SAE) is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome.

Drug-related AEs are those assessed by the investigator as either probably or possibly related.

Other malignancy excludes lymphoma, hepatosplenic T-cell lymphoma (HSTCL), leukemia, non-melanoma skin cancer (NMSC), and melanoma.

From the first dose of study drug until 70 days after the last dose (up to 33 weeks).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Martin Okun, MD, AbbVie

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 mei 2012

Primaire voltooiing (Werkelijk)

1 september 2013

Studie voltooiing (Werkelijk)

1 september 2013

Studieregistratiedata

Eerst ingediend

7 mei 2012

Eerst ingediend dat voldeed aan de QC-criteria

17 juli 2012

Eerst geplaatst (Schatting)

19 juli 2012

Updates van studierecords

Laatste update geplaatst (Schatting)

1 oktober 2014

Laatste update ingediend die voldeed aan QC-criteria

22 september 2014

Laatst geverifieerd

1 september 2014

Meer informatie

Termen gerelateerd aan deze studie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren